About Delcath systems, inc

About company

Delcath Systems and its proprietary targeted drug delivery system are at the forefront of the regional treatment of cancer. The Company's technology, known as Percutaneous Hepatic Perfusion (PHP), allows physicians to deliver significantly higher doses of anti-cancer drugs to the site of disease without exposing the patient's entire body to those same potent levels of drug. Initial clinical results from studies treating cancer in the liver confirm that delivering more drug to the tumor site, and less to the other regions of the body, enhances tumor shrinkage with improved quality of life over systemic cancer therapies. PHP is currently undergoing testing in Phase III and Phase II clinical trials for a variety of cancers of the liver.